Shots:
- The approval is based on 12mos. results of PINNACLE FLX study assessing the WATCHMAN FLX device as an alternative to NOACs and other OAC medications. The study met its 1EPs demonstrating a low rate of major procedure-related safety events (0.5% @7days post-procedure) and high rate of effective LAAC (100% with peri-device flow < 5mm @12mos. post-procedure) and showed a high implant success rate of 98.8%
- The company is also evaluating the device in OPTION study for patients with NVAF undergoing cardiac ablation procedure comparing it to oral anticoagulants as well as in the CHAMPION-AF trial that assess the device against NOACs in a broader OAC-eligible patient population
- The WATCHMAN FLX device is indicated to reduce the risk of stroke in patients with NVAF by permanently closing off the left atrial appendage and is available in broader size options to treat a wider range of patient anatomies. The device receives CE mark in Mar’2019 and will immediately commence a launch of the device in the US
Click here to read full press release/ article | Ref: Businesswire | Image: Boston Scientific
